Raymond James reiterates Strong Buy on Aveanna stock after beat
Raymond James reiterated a Strong Buy rating and $15.00 price target for Aveanna Healthcare (AVAH) after its Q3 2026 results beat estimates. AVAH reported adjusted EBITDA of $100.1M, 7.5% above consensus, and raised its 2026 EBITDA guidance to at least $374M. The stock trades at $13.09, with 13% upside to the target. RBC Capital increased its price target to $16.00, citing positive market positioning.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance lift provide a fresh catalyst that could drive the stock higher in the short term.
Market read
The article delivers primary company news with new guidance and analyst upgrade, offering a clear trading opportunity.
What to watch
Potential headwinds from Medicaid reimbursement changes could temper growth.
Background
Aveanna Healthcare reported Q3 2026 results beating estimates and raised its full‑year EBITDA guidance.
Ticker impact
Raymond James reiterated a Strong Buy on Aveanna (AVAH) and raised its 2026 EBITDA guidance, setting a $15 price target versus the current $13.09 price.
likely upside as the market prices in the higher EBITDA guidance and $15 target
Analyst upgrade with concrete target and guidance lift provides a clear, time‑sensitive catalyst.
Market effects
Positive guidance may lift other home‑health providers as the sector shows earnings strength.
U.S. healthcare services sector could see modest gains.
Limited to U.S. small‑cap healthcare space.
Counterpoint
The guidance raise may already be priced in, limiting upside.
Key entities
- AnalystRaymond James
Reiterated Strong Buy and set $15 price target.
- CompanyAveanna Healthcare Holdings Inc.
Reported Q3 results and raised guidance.

